{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:04:03Z","timestamp":1793865843047,"version":"4.6.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":765,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41379-020-0581-5","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T06:02:33Z","timestamp":1590991353000},"page":"2397-2406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9190-2450","authenticated-orcid":false,"given":"Erik A.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9155-556X","authenticated-orcid":false,"given":"Meagan","family":"Montesion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikunj","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwa","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean C.","family":"Pavlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan S.","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Venstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Elvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Jon","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Y.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7306-8813","authenticated-orcid":false,"given":"Mark C.","family":"Mochel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-020-0581-5_bib1","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N. Engl J Med"},{"key":"10.1038\/s41379-020-0581-5_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"10.1038\/s41379-020-0581-5_bib3","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1755-148X.2010.00778.x","article-title":"Genetic and morphologic features for melanoma classification","volume":"23","author":"Broekaert","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1038\/s41379-020-0581-5_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1038\/s41379-020-0581-5_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/pcmr.12560","article-title":"Kinase gene fusions in defined subsets of melanoma","volume":"30","author":"Turner","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1038\/s41379-020-0581-5_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pathol.2015.12.007","article-title":"Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy","volume":"48","author":"Wiesner","year":"2016","journal-title":"Pathology"},{"key":"10.1038\/s41379-020-0581-5_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat Commun"},{"key":"10.1038\/s41379-020-0581-5_bib8","doi-asserted-by":"crossref","unstructured":"Williams EA, Shah N, Montesion M, Sharaf R, Pavlick DC, Sokol ES, et al. Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles. Mod Pathol. 2020. https:\/\/doi.org\/10.1038\/s41379-020-0510-7. [Epub ahead of print].","DOI":"10.1038\/s41379-020-0510-7"},{"key":"10.1038\/s41379-020-0581-5_bib9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.celrep.2019.09.009","article-title":"Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses","volume":"29","author":"Botton","year":"2019","journal-title":"Cell Rep."},{"key":"10.1038\/s41379-020-0581-5_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ng.1026","article-title":"Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma","volume":"44","author":"Nikolaev","year":"2012","journal-title":"Nat Genet"},{"key":"10.1038\/s41379-020-0581-5_bib11","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jid.2019.01.027","article-title":"Dynamic evolution of clonal composition and neoantigen landscape in recurrent metastatic melanoma with a rare combination of driver mutations","volume":"139","author":"Davidson","year":"2019","journal-title":"J Investig Dermatol"},{"key":"10.1038\/s41379-020-0581-5_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell."},{"key":"10.1038\/s41379-020-0581-5_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/gcc.22247","article-title":"MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis","volume":"54","author":"Nelson","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1038\/s41379-020-0581-5_bib14","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2014-05-577361","article-title":"High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis","volume":"124","author":"Brown","year":"2014","journal-title":"Blood."},{"key":"10.1038\/s41379-020-0581-5_bib15","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","article-title":"Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis","volume":"124","author":"Chakraborty","year":"2014","journal-title":"Blood."},{"key":"10.1038\/s41379-020-0581-5_bib16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2159-8290.CD-17-1452","article-title":"Allele-specific mechanisms of activation of mek1 mutants determine their properties","volume":"8","author":"Gao","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1038\/s41379-020-0581-5_bib17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1038\/s41379-020-0581-5_bib18","first-page":"e1005965","article-title":"A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal","volume":"14","author":"Sun","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1038\/s41379-020-0581-5_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"10.1038\/s41379-020-0581-5_bib20","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J Mol Diagn"},{"key":"10.1038\/s41379-020-0581-5_bib21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jmoldx.2018.05.004","article-title":"Analytical validation of a hybrid capture\u2013based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA","volume":"20","author":"Clark","year":"2018","journal-title":"J Mol Diagnostics."},{"key":"10.1038\/s41379-020-0581-5_bib22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1200\/JCO.2018.36.4_suppl.569","article-title":"Comprehensive genomic profiling of ctDNA in patients with colon cancer and its fidelity to the genomics of the tumor biopsy","volume":"36","author":"Gregg","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0581-5_bib23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1038\/s41379-020-0581-5_bib24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1038\/s41379-020-0581-5_bib25","unstructured":"Elder DE, Barnhill RL, Bastian BC, Cook MG, de la Fouchardiere A, Gerami P, et al. Melanocytic tumours. In: Elder DE, Massi D, Scolyer RA, and Willemze RE, editor. World Health Organization 2018 Classification of Skin Tumours. Lyon, France: International Agency for Research on Cancer, 2018. p. 65\u201377."},{"key":"10.1038\/s41379-020-0581-5_bib26","doi-asserted-by":"crossref","first-page":"eaar6795","DOI":"10.1126\/scisignal.aar6795","article-title":"Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis","volume":"11","author":"Yuan","year":"2018","journal-title":"Sci Signal."},{"key":"10.1038\/s41379-020-0581-5_bib27","first-page":"30098","article-title":"Identification of novel CD74-NRG2\u03b1 fusion from comprehensive profiling of lung adenocarcinoma in Japanese never or light smokers","volume":"S1556-0864","author":"Kohsaka","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-020-0581-5_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00758-3","article-title":"Combined activation of MAP kinase pathway and \u03b2-catenin signaling cause deep penetrating nevi","volume":"8","author":"Yeh","year":"2017","journal-title":"Nat Commun."},{"key":"10.1038\/s41379-020-0581-5_bib29","doi-asserted-by":"crossref","first-page":"52304","DOI":"10.18632\/oncotarget.17014","article-title":"Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1\/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis","volume":"8","author":"Emelyanova","year":"2017","journal-title":"Oncotarget."},{"key":"10.1038\/s41379-020-0581-5_bib30","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3389\/fonc.2018.00584","article-title":"The prognostic significance of low-frequency somatic mutations in metastatic cutaneous melanoma","volume":"8","author":"Zhao","year":"2019","journal-title":"Front Oncol."},{"key":"10.1038\/s41379-020-0581-5_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1158\/2159-8290.CD-12-0022","article-title":"Preexisting MEK1 Exon 3 mutations in V600E\/KBRAF melanomas Do Not confer resistance to BRAF inhibitors","volume":"2","author":"Shi","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1038\/s41379-020-0581-5_bib32","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0581-5_bib33","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2012.44.7888","article-title":"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma","volume":"31","author":"Trunzer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0581-5_bib34","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1541-7786.MCR-17-0211","article-title":"BRAF-inhibitor associated MEK mutations increase RAF-dependent and -independent enzymatic activity","volume":"15","author":"Emery","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1038\/s41379-020-0581-5_bib35","doi-asserted-by":"crossref","first-page":"20411","DOI":"10.1073\/pnas.0905833106","article-title":"MEK1 mutations confer resistance to MEK and B-RAF inhibition","volume":"106","author":"Emery","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/s41379-020-0581-5_bib36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/1078-0432.CCR-14-0759","article-title":"Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients","volume":"21","author":"Carlino","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-020-0581-5_bib37","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1038\/s41379-020-0581-5_bib38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1038\/s41379-020-0581-5_bib39","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.2147\/OTT.S182721","article-title":"Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of us food and drug administration-approved targeted therapy in advanced melanoma","volume":"11","author":"Kakadia","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1038\/s41379-020-0581-5_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2019.00268","article-title":"Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies","volume":"9","author":"Luebker","year":"2019","journal-title":"Front Oncol"},{"key":"10.1038\/s41379-020-0581-5_bib41","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/2159-8290.CD-12-0128","article-title":"Making sense of MEK1 mutations in intrinsic and acquired BRAF inhibitor resistance","volume":"2","author":"Paraiso","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1038\/s41379-020-0581-5_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00070","article-title":"Trametinib-induced remission of an MEK1-mutated langerhans cell histiocytosis","volume":"1","author":"Papapanagiotou","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1038\/s41379-020-0581-5_bib43","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1164\/rccm.201802-0275LE","article-title":"Response to trametinib of a pulmonary Langerhans cell histiocytosis harboring a MAP2K1 deletion","volume":"198","author":"Lorillon","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1038\/s41379-020-0581-5_bib44","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.21037\/jgo.2019.08.02","article-title":"A case of class 3 MEK1 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors","volume":"10","author":"Wang","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"10.1038\/s41379-020-0581-5_bib45","doi-asserted-by":"crossref","first-page":"e21027","DOI":"10.1200\/JCO.2019.37.15_suppl.e21027","article-title":"Targeting MAP2K1 mutation with trametinib in a triple wild-type melanoma patient","volume":"37","author":"Homicsko","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0581-5_bib46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1158\/2159-8290.CD-17-1355","article-title":"ERK inhibition: a new front in the war against mapk pathway-driven cancers?","volume":"8","author":"Smalley","year":"2018","journal-title":"Cancer Disco"},{"key":"10.1038\/s41379-020-0581-5_bib47","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1158\/2159-8290.CD-18-0192","article-title":"Oncogenic mutants of MEK1: a trilogy unfolds","volume":"8","author":"Maust","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1038\/s41379-020-0581-5_bib48","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/PAS.0000000000000902","article-title":"Genomic analysis of pigmented epithelioid melanocytomas reveals recurrent alterations in PRKAR1A, and PRKCA Genes","volume":"41","author":"Cohen","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-020-0581-5_bib49","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/PAS.0000000000001195","article-title":"Distinct genomic patterns in pigmented epithelioid melanocytoma: a molecular and histologic analysis of 16 Cases","volume":"43","author":"Isales","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-020-0581-5_bib50","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/PAS.0000000000001213","article-title":"Activating structural alterations in MAPK genes are distinct genetic drivers in a unique subgroup of spitzoid neoplasms","volume":"43","author":"Quan","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-020-0581-5_bib51","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1371\/journal.pmed.0050120","article-title":"Improving melanoma classification by integrating genetic and morphologic features","volume":"5","author":"Viros","year":"2008","journal-title":"PLoS Med"},{"key":"10.1038\/s41379-020-0581-5_bib52","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jaad.2017.09.022","article-title":"Langerhans cell histiocytosis: a neoplastic disorder driven by Ras-ERK pathway mutations","volume":"78","author":"Tran","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/s41379-020-0581-5_bib53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.humpath.2015.12.029","article-title":"BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: A study of 50 cases","volume":"52","author":"Alayed","year":"2016","journal-title":"Hum Pathol."},{"key":"10.1038\/s41379-020-0581-5_bib54","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/PAS.0000000000001057","article-title":"Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans cell histiocytosis","volume":"42","author":"McGinnis","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-020-0581-5_bib55","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2017-01-765107","article-title":"Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations","volume":"130","author":"Durham","year":"2017","journal-title":"Blood."},{"key":"10.1038\/s41379-020-0581-5_bib56","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2014","journal-title":"Nat Genet."},{"key":"10.1038\/s41379-020-0581-5_bib57","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/10428194.2016.1185786","article-title":"Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant","volume":"58","author":"Mason","year":"2017","journal-title":"Leuk Lymphoma."},{"key":"10.1038\/s41379-020-0581-5_bib58","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/modpathol.2017.55","article-title":"Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease","volume":"30","author":"Garces","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-020-0581-5_bib59","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1158\/0008-5472.CAN-08-0099","article-title":"Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma","volume":"68","author":"Marks","year":"2008","journal-title":"Cancer Res."},{"key":"10.1038\/s41379-020-0581-5_bib60","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1158\/1078-0432.CCR-14-2124","article-title":"MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking","volume":"21","author":"Arcila","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-020-0581-5_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13460-3","article-title":"Genomic and immune profiling of pre-invasive lung adenocarcinoma","volume":"10","author":"Chen","year":"2019","journal-title":"Nat Commun."},{"key":"10.1038\/s41379-020-0581-5_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers11060859","article-title":"Genomic profiling of KRAS\/NRAS\/BRAF\/PIK3CA wild-type metastatic colorectal cancer patients reveals novel mutations in genes potentially associated with resistance to anti-EGFR agents","volume":"11","author":"Rachiglio","year":"2019","journal-title":"Cancers"},{"key":"10.1038\/s41379-020-0581-5_bib63","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ajhg.2017.01.018","article-title":"Somatic MAP2K1 mutations are associated with extracranial arteriovenous malformation","volume":"100","author":"Couto","year":"2017","journal-title":"Am J Hum Genet"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-020-0581-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-020-0581-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222004124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222004124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-020-0581-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:34:10Z","timestamp":1760229250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222004124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0893395222004124"],"URL":"https:\/\/doi.org\/10.1038\/s41379-020-0581-5","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-020-0581-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors.","name":"copyright","label":"Copyright"}]}}